Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy.

[1]  S. Furlan,et al.  Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT , 2021, JCI insight.

[2]  Jeffrey A. Cohen,et al.  Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions , 2021, The Lancet.

[3]  G. Hill,et al.  Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD , 2020, Nature Reviews Clinical Oncology.

[4]  Xiao-jun Huang,et al.  Treatment and unmet needs in steroid-refractory acute graft-versus-host disease , 2020, Leukemia.

[5]  D. Hashimoto,et al.  Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis , 2019, Bone Marrow Transplantation.

[6]  T. Ziemssen,et al.  Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients , 2018, Front. Immunol..

[7]  D. Burrin,et al.  Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  M. Ratajczak,et al.  Evidence for the involvement of sphingosine-1-phosphate in the homing and engraftment of hematopoietic stem cells to bone marrow , 2015, Oncotarget.

[9]  J. Ritz,et al.  Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  S. Chimenti,et al.  Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial , 2014, The Lancet.

[11]  M. Goldman,et al.  Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis , 2014, Expert opinion on drug safety.

[12]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[13]  W. Wiktor-Jedrzejczak,et al.  Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice , 2014, Bone Marrow Transplantation.

[14]  Y. Itoyama,et al.  Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension , 2014, BMC Neurology.

[15]  Y. Itoyama,et al.  A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis , 2012, Multiple sclerosis.

[16]  M. Díaz-Beyá,et al.  The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  T. Nishida,et al.  A Novel Sphingosine 1-Phosphate Receptor Agonist, 2-Amino-2-propanediol Hydrochloride (KRP-203), Regulates Chronic Colitis in Interleukin-10 Gene-Deficient Mice , 2008, Journal of Pharmacology and Experimental Therapeutics.

[18]  J. Tolar,et al.  Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). , 2007, Blood.

[19]  M. Tanimoto,et al.  FTY720 enhances the activation‐induced apoptosis of donor T cells and modulates graft‐versus‐host disease , 2007, European journal of immunology.

[20]  O. Özdoğan,et al.  Causes and Risk Factors for Liver Injury Following Bone Marrow Transplantation , 2003, Journal of clinical gastroenterology.

[21]  R. Bronson,et al.  Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. , 2003, The Journal of clinical investigation.

[22]  N. Schmitz,et al.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. , 2002, Blood.

[23]  B. K. Kim,et al.  Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study , 2000, Bone Marrow Transplantation.

[24]  R. Zinkernagel,et al.  FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory1 , 2000, The Journal of Immunology.